Mirati Therapeutics Inc.
Quick facts
Phase 3 pipeline
- MRTX849 · Oncology
MRTX849 is a small-molecule inhibitor that selectively targets KRAS G12C mutations, blocking oncogenic signaling in cancer cells.
Phase 2 pipeline
- Enfortumab Vedotin-Ejfv · Oncology
Enfortumab vedotin-ejfv is a monoclonal antibody-drug conjugate that targets Nectin-4. - MGCD265
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Mirati Therapeutics Inc.
What is Mirati Therapeutics Inc.'s pipeline?
Mirati Therapeutics Inc. has 1 drugs in Phase 3, 2 in Phase 2, 1 in Phase 1. Late-stage candidates include MRTX849.
Related
- Sector hub: All tracked pharma companies